Mary is the associate editorial director for The American Journal of Managed Care® (AJMC®), The Center for Biosimilars®, and Evidence-Based Oncology™. She joined AJMC® in 2013 and oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®.
She has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn or Twitter.
Additional Results From POLARIX Study Show Improved PFS With No Reduction in HRQOL
January 29th 2023New data from the POLARIX STUDY show that substituting polatuzumab vedotin for 1 part of a classic first-line chemotherapy combination to manage diffuse large B-cell lymphoma improved progression-free survival without compromising health-related quality-of-life.
Read More
PolaR-ICE Effective as Second-line Treatment in DLBCL, Bridge to Autologous Stem Cell Transplant
January 28th 2023Results presented during the 64th American Society of Hematology Annual Meeting and Exposition could offer an effective option for those with relapsed or refractory DLBCL, even as chimeric antigen receptor T-cell therapy becomes standard of care for many patients.
Read More
Tucatinib Plus Trastuzumab Approved for RAS Wild-type, HER2+ Unresectable or Metastatic CRC
January 19th 2023The combination of tucatinib and trastuzumab received accelerated approval from the FDA to treat adults with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer (mCRC) that advances after treatment with specific types of chemotherapy.
Read More
From Lymphomas to Myeloma, Bispecific Antibodies Make a Big Splash at ASH
January 14th 2023At the 2022 annual meeting of the American Society of Hematology (ASH), customized cancer immunotherapy treatments now share the limelight with bispecific antibodies, which made news across disease states from large B-cell lymphoma to follicular lymphoma to multiple myeloma; as their name suggests, these treatments aim at 2 targets, increasing their potency against cancer.
Read More
Dr Davey Daniel Talks Approval of Cemiplimab With Chemotherapy for First-line NSCLC
December 21st 2022Cemiplimab with chemotherapy appears to offer value comparable to other options and may be "an important tool to use" in first-line treatment of non-small cell lung cancer (NSCLC), said Davey Daniel, MD, chief medical officer for OneOncology, lung cancer specialist.
Read More
How Ochsner, Xavier Are Working Together to Make Louisiana a Healthy State
December 15th 2022Leaders from Ochsner, Xavier, and their partners gathered on September 13, 2022, in New Orleans to offer an overview of the Healthy State initiative during a session of the Institute for Value-Based Medicine®.
Read More
FDA Leader at ASH: Decentralized Clinical Trials Aren’t “All or Nothing”
December 12th 2022Nicole Gormley, MD, acting director of the Division of Hematology Products at FDA, explained that the agency wants to maintain momentum gained during the pandemic that moved clinical trials beyond the walls of academic centers.
Read More
After a Week, Efgartigimod Lets 38% of Patients With ITP Reach Platelet Counts to Avoid Bleeding
December 11th 2022Results of a phase 3 study presented Sunday found efgartigimod allowed a third of patients with immune thrombocytopenia (ITP) to quickly achieve platelet levels that signal an ability to avoid sudden bleeding events.
Read More
Dr Douglas Mann on Next Steps to Studying Gene Editing in Heart Failure
December 9th 2022Initial data on NTLA-2001, which is a novel investigative intravenous agent that works to prevent development of cardiac transthyretin (ATTR) amyloidosis by targeting the TTR gene and TTR protein levels, were presented at this year’s American Heart Association’s Scientific Sessions in Chicago.
Read More
What Predicts Good Outcomes With Axi-cel? Investigators Support “Timely” Treatment
December 3rd 2022Investigators from Fred Hutchison Cancer Research Center hoped to gain insights into what factors can predict success with axi-cel in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Read More
Dr Samyukta Mullangi: COVID-19 Has Spurred Us to Ask How We Can Innovate Care Delivery
December 1st 2022During an Institute for Value-Based Medicine® event held in New York City, Samyukta Mullangi, MD, MBA, fellow in medical oncology at Memorial Sloan Kettering Cancer Center, discussed how disruptions from the COVID-19 pandemic are ushering in health care delivery reform.
Read More